All In Biotech

Drug Trial Radar · NCT05928806

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 25, 2023

Primary completion

Nov 10, 2026

Study completion Nov 10, 2027

Sponsor

Lead sponsor
Michael B. Atkins, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Agenus Inc.; Georgetown University
First posted
Jul 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included. This study utilizes a Simon's two stage design which is described in the protocol. Patients randomized to Arm A will receive botensilimab in combination with balstilimab. Patients randomized to Arm B will receive ipilimumab in combination with nivolumab. Study treatment on both arms will continue until toxicity, disease progression or a maximum of 96 total weeks (12 weeks induction, 84 weeks maintenance).

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

  • BotensilimabDrug

    Botensilimab 75mg IV

  • BalstilimabDrug

    Balstilimab 450mg IV

  • IpilimumabDrug

    Ipilimumab 1mg/kg IV

  • NivolumabDrug

    Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the objective response rate (ORR) of botensilimab + balstilimab in patients with treatment naïve metastatic ccRCC relative to the ORR of patients treated with ipilimumab + nivolumab.Time frame: 5 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Yale University, Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber - Partners Cancer Care, Inc

    Boston, Massachusetts

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Cornell University

    Ithaca, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Penn Medicine Abramson Cancer Center

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.